Please assess the completion status of the following clinical trial:

Trial Title: Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with liver cirrhosis and ascites~* Meets all criteria for nosocomial SBP as outlined below~  * Ascitic fluid polymorphonuclear cells count \>250/mm3~ * Onset of signs and symptoms of infection after 72 hours of hospitalization~Exclusion Criteria:~* Hepatocellular carcinoma beyond the Milan criteria~* Abdominal surgery within 4 weeks~* Evidence of secondary peritonitis, pancreatitis or peritoneal carcinomatosis~* Significant heart or respiratory failure~* Allergy to ceftazidime, meropenem or daptomycin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Daptomycin + Meropenem (Type: EXPERIMENTAL): 30 patients with cirrhosis and nosocomial SBP
- Ceftazidime (Type: ACTIVE_COMPARATOR): 30 patients with cirrhosis and nosocomial SBP

Based on this trial design, predict the completion outcome and termination type (if applicable).